This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2000 Jan 15;355(9199):160-1.

doi: 10.1016/S0140-6736(99)00430-4.

Response of metastatic breast cancer to trastuzumab?

D M Barnes¹, D W Miles

Affiliations

PMID: 10675110
DOI: 10.1016/S0140-6736(99)00430-4

Response of metastatic breast cancer to trastuzumab?

D M Barnes et al. Lancet. 2000.

. 2000 Jan 15;355(9199):160-1.

doi: 10.1016/S0140-6736(99)00430-4.

Authors

D M Barnes¹, D W Miles

Affiliation

¹ ICRF Breast Pathology Laboratory and ICRF Breast Biology Group, Guy's Hospital, London, UK.

PMID: 10675110
DOI: 10.1016/S0140-6736(99)00430-4

No abstract available

PubMed Disclaimer

Similar articles

More than one way to look for HER2.
Check W. Check W. CAP Today. 1999 Mar;13(3):1, 40-2, 46, passim. CAP Today. 1999. PMID: 10350906 No abstract available.
Monoclonal antibody approved for metastatic breast cancer.
[No authors listed] [No authors listed] Oncology (Williston Park). 1998 Dec;12(12):1727. Oncology (Williston Park). 1998. PMID: 9874846 No abstract available.
The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y, Suzuki Y, Saito Y, Umemura S. Tokuda Y, et al. Breast Cancer. 2009;16(4):295-300. doi: 10.1007/s12282-009-0142-8. Epub 2009 Jul 17. Breast Cancer. 2009. PMID: 19609647 Review.
Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug?
Livingston RB, Esteva FJ. Livingston RB, et al. Oncologist. 2001;6(4):315-6. doi: 10.1634/theoncologist.6-4-315. Oncologist. 2001. PMID: 11524548 No abstract available.
[Trastuzumab in metastatic breast carcinoma].
Susnjar S, Bosnjak S, Radulovic S. Susnjar S, et al. Srp Arh Celok Lek. 2001 May-Jun;129(5-6):147-52. Srp Arh Celok Lek. 2001. PMID: 11797464 Review. Serbian. No abstract available.

See all similar articles

Cited by

Therapeutic applications of monoclonal antibodies.
Berger M, Shankar V, Vafai A. Berger M, et al. Am J Med Sci. 2002 Jul;324(1):14-30. doi: 10.1097/00000441-200207000-00004. Am J Med Sci. 2002. PMID: 12120821 Free PMC article. Review.
Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7.
Liu Q, Li S, Qiu Y, Zhang J, Rios FJ, Zou Z, Touyz RM. Liu Q, et al. Front Cardiovasc Med. 2023 Feb 3;10:1002438. doi: 10.3389/fcvm.2023.1002438. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36818331 Free PMC article. Review.
EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.
Shen L, Shui Y, Wang X, Sheng L, Yang Z, Xue D, Wei Q. Shen L, et al. BMC Cancer. 2008 Aug 12;8:232. doi: 10.1186/1471-2407-8-232. BMC Cancer. 2008. PMID: 18700025 Free PMC article.
Whither high-dose chemotherapy in breast cancer?
Mayer A, Earl H. Mayer A, et al. Breast Cancer Res. 2001;3(1):8-10. doi: 10.1186/bcr262. Epub 2000 Nov 8. Breast Cancer Res. 2001. PMID: 11250740 Free PMC article. Review.
Recent advances in anti-angiogenic therapy of cancer.
Samant RS, Shevde LA. Samant RS, et al. Oncotarget. 2011 Mar;2(3):122-34. doi: 10.18632/oncotarget.234. Oncotarget. 2011. PMID: 21399234 Free PMC article. Review.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information